Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05454839
Other study ID # H-42726
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 8, 2022
Est. completion date December 2024

Study information

Verified date December 2023
Source Boston University
Contact Sydney Rosen
Phone +18572077909
Email sbrosen@bu.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

With the advent of universal eligibility for HIV treatment ("treat all") and same-day and community-based antiretroviral therapy (ART) initiation, retention in care after a patient has started ART remains the main challenge to achieving optimal outcomes in HIV treatment programs. Consistently across both time and geography, the highest risk for loss from care is during a patient's first six months after ART initiation, with about quarter of all patients not retained by the end of month 6. One of the reasons for the high attrition from care in this early retention period is that the model of care offered to most newly-initiating and re-initiating patients has barely evolved from its original outlines. Patients in their first six months on ART are generally not eligible for lower-intensity, patient-centered "differentiated service delivery" models that make remaining in care easier for experienced patients. Instead, most early patients must still make multiple clinic visits that include clinical consultations with providers, and most can receive only 1-2 month supplies of medications at a time. This protocol is for the PREFER-South Africa study, an activity of the Retain6 project. Retain6 aims to develop new models of care for patients' first six months on ART. PREFER-South Africa will collect data on patients' characteristics, clinical and non-clinical needs, and preferences for different types of services during their first six months after initiating ART. The investigators will conduct an observational, prospective cohort survey of newly-initiated or re-initiated adult ART patients at a selected set of 18 healthcare facilities in South Africa. Results are expected to inform the design of better models of service delivery for the early treatment period.


Recruitment information / eligibility

Status Recruiting
Enrollment 2500
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Living with HIV and on ART for 0-6 six months at the study site - = 18 years old (18 and older considered adult for research purposes in South Africa) - Presented at the study site for routine HIV-related care - Provide written informed consent to participate. - For patients providing a dried blood spot specimen, initiating or re-initiating ART at the study enrollment visit. Exclusion Criteria: - Unable to communicate in any of the languages into which the questionnaire has been translated or that is known to the research assistant - Not physically, mentally, or emotionally able to participate in the study, in the opinion of the investigators or study staff - Unwilling to take the time required to complete the questionnaire on the day of consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Survey
Interviewer-administered survey
Focus group
Focus group for selected participants

Locations

Country Name City State
South Africa Mhairi Maskew Johannesburg Gauteng
Zambia Clinton Health Access Initiative Lusaka

Sponsors (4)

Lead Sponsor Collaborator
Boston University Bill and Melinda Gates Foundation, Clinton Health Access Initiative-Zambia, University of the Witwatersrand, South Africa

Countries where clinical trial is conducted

South Africa,  Zambia, 

References & Publications (1)

Rosen S, Grimsrud A, Ehrenkranz P, Katz I. Models of service delivery for optimizing a patient's first six months on antiretroviral therapy for HIV: an applied research agenda. Gates Open Res. 2020 Jul 29;4:116. doi: 10.12688/gatesopenres.13159.1. eCollection 2020. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Retention Not missing a scheduled clinical or medication pickup visit during the first 6 months after treatment initiation by more than 28 days. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT03477279 - Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi N/A